SCHEDULE 13G/A: Van Herk Entities Disclose 10.9% Stake in ProQR Therapeutics N.V.

A group of Dutch investment entities and foundations, led by Adrianus van Herk, have disclosed a collective beneficial ownership of 10.9% in ProQR Therapeutics N.V., totaling 11,461,995 ordinary shares.

Summary

• Van Herk Investments B.V. and eight related entities and individuals, including Adrianus van Herk, have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in ProQR Therapeutics N.V.
• The reporting persons collectively beneficially own 11,461,995 Ordinary Shares of ProQR Therapeutics N.V.
• This ownership represents 10.9% of the total issued and outstanding Ordinary Shares of ProQR Therapeutics N.V., based on 105,212,527 shares outstanding as of December 31, 2024.
• Van Herk Investments B.V. holds sole voting and dispositive power over all 11,461,995 shares.
• Other reporting persons, including Van Herk Investments THI B.V., Van Herk Private Equity Investments B.V., Stichting Administratiekantoor Penulata, Van Herk Management Services B.V., Onroerend Goed Beheeren Beleggingsmaatschappij A. van Herk B.V., A. van Herk Holding B.V., Stichting Administratiekantoor Abchrys, and Adrianus van Herk, share voting and dispositive power over these shares due to their hierarchical control and equity interests.
• The filing certifies that the shares were not acquired or held for the purpose of changing or influencing the control of ProQR Therapeutics N.V., except for activities solely related to a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing neutral information without positive or negative implications for the company's performance or outlook.

Industry Context

This filing is a standard disclosure of a significant ownership stake by an institutional investor group in a publicly traded biotechnology company. Such disclosures provide transparency regarding major shareholders and can indicate long-term investment interest, but do not typically reflect operational or financial performance trends within the biotechnology industry.

Related Party Transactions

• The filing details a complex hierarchical structure of ownership and control among the reporting persons, where Adrianus van Herk ultimately controls multiple entities (foundations, holding companies, investment companies) that collectively hold the shares in ProQR Therapeutics N.V. This structure defines the shared voting and dispositive power among the various Van Herk entities.

Stakeholder Impact

• Shareholders: The disclosure of a significant 10.9% stake by a group of related entities provides transparency regarding a major investor's position, which can influence market perception and potentially signal long-term commitment or strategic interest in the company.

Key Dates

Keywords

ProQR Therapeutics N.V., Van Herk Investments, Beneficial Ownership, Schedule 13G, Equity Stake, Biotechnology, Pharmaceuticals, Netherlands, Institutional Investor